جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

32 مُخرَج نتائج البحث عن «Placebo»

مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (3) · e106154-e106154

Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.

melasmalaser therapyQ-switched Nd:YAG laserpicosecond laser
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (2) · e103029-e103029

Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.

ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
مقالوصول مفتوح20261استشهاد· Semantic Scholar

Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis

Health Economics Review · مجلد 16 (1)

BACKGROUND: Given the rising incidence of endometrial cancer in Saudi Arabia, the integration of high-cost therapeutics, such as dostarlimab (DSR), for primary advanced or recurrent (pA/rEC) disease necessitates rigorous economic appraisal. Therefore, this study aimed to evaluate the cost-utility of first-line dostarlimab plus carboplatin-paclitaxel (DSR + CP) versus placebo plus carboplatin-paclitaxel (PBO + CP) from the perspective of the Saudi healthcare payer. METHODS: A partitioned survival model was constructed to simulate patient prognosis across three health states: progression-free disease, progressive disease, and death. The model parameters were derived from the clinical efficacy data of the RUBY trial and the local cost inputs. The primary outcome was the incremental cost-effectiveness ratio (ICER), the robustness of which was evaluated via comprehensive deterministic and probabilistic sensitivity analyses to characterize parameter uncertainty. RESULTS: For the overall pA/rEC population, the DSR + CP regimen yielded an incremental 1.55 quality-adjusted life-years (QALYs) at an additional cost of $144,716, resulting in an ICER of $93,244 per QALY. Cost-effectiveness was more favorable in the mismatch repair deficient (dMMR) subgroup (ICER: $82,754/QALY) than in the mismatch repair proficient (pMMR) cohort (ICER: $132,571/QALY). The ICER is the most sensitive to the acquisition cost of the DSR. At a willingness-to-pay threshold of $90,000/QALY, the probability of DSR + CP being cost-effective was 83.9% for the dMMR subgroup. CONCLUSION: This economic evaluation indicates that DSR + CP constitutes a cost-effective intervention for pA/rEC within the dMMR subpopulation. These findings provide strong evidence for a tailored reimbursement policy that effectively utilizes resources by connecting clinical benefits with economic value in the management of pA/rEC.

dostarlimabendometrial cancercarboplatin-paclitaxelcost-utility analysis
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Efficacy of Selective Serotonin Reuptake Inhibitors for the Treatment of Chronic Pain and Comorbid Depression in Individuals With Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (2) · e102998-e102998

Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.

fibromyalgiaselective serotonin reuptake inhibitorscomorbid depressionchronic widespread pain
مراجعةوصول مفتوح2026

Early prophylactic low-dose hydrocortisone for bronchopulmonary dysplasia prevention in extremely preterm infants: a systematic review and meta-analysis

Frontiers in Pediatrics · مجلد 14

Background Early prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain. Objective To evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation. Methods This systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs). Results Fourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups. Conclusion Current evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/prospero/view/CRD420261402317 , PROSPERO CRD420261402317.

cortisolbronchopulmonary dysplasiaextremely preterm infantsadrenal insufficiency
مراجعةوصول مفتوح2026

Evaluating the therapeutic benefit of bacterial lysates in chronic obstructive pulmonary disease: a systematic review and meta-analysis

Frontiers in Medicine · مجلد 13

Background Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Results Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Conclusion Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. Systematic Review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783 , PROSPERO CRD42024570783.

chronic obstructive pulmonary diseasebacterial extractsCOPD exacerbationshospitalization
مقالوصول مفتوح2026

Tavapadon in Parkinson’s disease: D1/D5 receptor pharmacology, clinical evidence, and translational perspectives

Frontiers in Aging Neuroscience · مجلد 18

Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.

Parkinson's diseasedopamine D1 receptordopamine D5 receptormotor fluctuations
مراجعةوصول مفتوح2026

Comparative effectiveness of ultrasound-guided regional nerve blocks for hip fracture analgesia in the emergency department: a systematic review

— · مجلد 3 (4)

Hip fracture produces severe acute pain and complicates emergency assessment and transfers. Regional nerve blocks provide targeted analgesia within multimodal treatment. This review compared ultrasound-guided techniques for adults receiving emergency department care. PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched through 31 May 2026. Two authors independently screened studies and extracted data. Randomized trials comparing emergency department initiated single-injection blocks with another ultrasound-guided block, placebo, or systemic analgesia were synthesized narratively. Fourteen randomized trials evaluated femoral, fascia iliaca, and pericapsular nerve group blocks. Femoral blocks generally improved analgesia and reduced opioid exposure relative to systemic treatment, with neutral findings in one short-term fentanyl comparison. Femoral and fascia iliaca blocks produced similar pain reductions in a direct comparison. Supra-inguinal fascia iliaca block improved movement pain relative to the classical approach. Pericapsular nerve group block improved early pain relief relative to infra-inguinal fascia iliaca block and reduced rescue analgesia relative to sham. Opioid reduction varied across trials, including a fascia iliaca study reporting identical median six-hour morphine consumption. Ultrasound-guided blocks improve early hip fracture analgesia in emergency care. Technique selection depends on comparator, assessment timing, and patient characteristics. Data supports regional analgesia within multimodal pathways, without establishing one universally superior block.

hip fracturenerve blockultrasound-guided nerve blockfemoral nerve block
مراجعةوصول مفتوح2026

Rifaximin Versus Placebo for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (9) · e116820-e116820

Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.

rifaximinirritable bowel syndromeplacebo comparisonantibiotic therapy
مراجعةوصول مفتوح2026

Efficacy and Safety of Vernakalant for Cardioversion of Atrial Fibrillation and Flutter: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine · مجلد 15 (19) · 7406-7406

Background/Objectives: Vernakalant is an atrial-selective antiarrhythmic used for rapid pharmacological cardioversion of recent-onset atrial fibrillation. This systematic review and meta-analysis evaluated the efficacy and safety of vernakalant compared with placebo, active antiarrhythmic therapy, and electrical cardioversion. Methods: PubMed, Embase, Google Scholar, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to August 2026. Randomized clinical trials, clinical trials, and comparative observational studies evaluating vernakalant in adults with atrial fibrillation or atrial flutter were included. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using the Mantel–Haenszel random-effects model in RevMan 5.4. Results: Twenty controlled studies involving 4523 patients were included, of whom 2349 received vernakalant and 2174 received control therapy. Vernakalant significantly increased successful conversion to sinus rhythm compared with all controls (1234/2244 (55%) vs. 991/2147 (46.2%); RR = 1.63; 95% CI [1.34, 1.99]; p < 0.00001). The effect was strongest versus placebo (RR = 5.33; 95% CI [1.95, 14.60]; p = 0.001) and remained significant versus procainamide (111/178 (62.3%) vs. 83/172 (48.2%); RR = 1.29; 95% CI [1.07, 1.57]; p = 0.009) and flecainide (209/280 vs. 209/330 (63.3%); RR = 1.18; 95% CI [1.05, 1.33]; p = 0.007), but non-significant against amiodarone, propafenone, ibutilide, or electrical cardioversion. Safety outcomes did not differ significantly between groups, including all-cause mortality (RR = 1.23), drug discontinuation (RR = 0.98), serious adverse events (RR = 0.87), ventricular tachycardia (RR = 0.68), bradycardia (RR = 1.31), and hypotension (RR = 0.80). Conclusions: Vernakalant was associated with higher rates of conversion to sinus rhythm, while no statistically significant differences were observed in major safety outcomes. These findings support its use as a pharmacological option for rapid rhythm restoration in appropriately selected patients.

vernakalantatrial fibrillationatrial flutterpharmacological cardioversion
مقالوصول مفتوح2026

Evaluating the efficacy and safety of melatonin for sleep onset insomnia in children aged 6–12: a systematic review and meta-analysis

BMC Pediatrics

Abstract Background Melatonin is an endogenous hormone that regulates the body’s sleep-wake cycles. Due to several clinical trials, it is currently used as an exogenous supplement in pediatric patients who suffer from sleep-onset insomnia (SOI). Consequently, this systematic review and meta-analysis aimed to assess the evidence for the clinical efficacy of melatonin for SOI in children aged 6–12. Methods This systematic review and meta-analysis evaluated the efficacy and safety of Melatonin for sleep-onset insomnia in children aged 6–12 by conducting literature searches in PubMed (97), Google Scholar (111), OVID (33), and Web of Science (156) databases. We performed statistical tests using RevMan for meta-analysis. Heterogeneity was evaluated using the I2 statistic. To maintain the validity of the studies, each included study was assessed by the Cochrane Collaboration Risk of Bias (ROB) tool. The outcomes investigated were sleep onset time (SOT), sleep onset latency (SOL), total sleep time (TST), all-cause dropout rates, and adverse-event dropout rates. Results Three hundred ninety-eight records were identified, and 10 randomized clinical trials met the inclusion criteria. The results demonstrated that melatonin treatment group was associated with an earlier sleep onset time compared with placebo with a mean difference (MD) of -0.48 h (approximately 29 min earlier) (95% confidence interval [CI]: -0.93 to -0.02 h, p = 0.04). The heterogeneity between studies was moderate (I2 = 63%). On the other hand, it was noted that there has been noticed there was a remarkable reduction in sleep onset latency with melatonin compared to placebo, with an MD of -0.38 (95% CI: -0.57 to -0.20, p < 0.0001), with high heterogeneity (I2 = 82%). Conclusion Our study confirmed that melatonin has a marked effect regarding Sleep-onset insomnia in childhood. Therefore, we found there was a statistical and clinical improvement in sleep parameters such as sleep onset time (SOT) and total sleep time (TST) which demonstrated the safety and efficacy of melatonin. However, long-term efficacy and safety need to be addressed, especially in the pediatric population.

melatoninsleep onset insomniapediatric insomniachildren
مراجعةوصول مغلق2026

Systematic Review on the Effectiveness of Photobiomodulation Therapy on Enhancing Musculoskeletal Rehabilitation Outcomes after Total Knee and Hip Arthroplasty

Photobiomodulation Photomedicine and Laser Surgery · مجلد 44 (10) · 597-605

BACKGROUND: Total knee and hip arthroplasty (TKA/THA) effectively alleviate chronic pain and improve joint function and quality of life. However, postoperative recovery is often hindered by pain, edema, restricted range of motion (ROM), and muscle weakness, necessitating structured physical rehabilitation. Photobiomodulation Therapy (PBMT) has been proposed as an adjunct modality to enhance rehabilitation outcomes. This systematic review evaluates the efficacy of PBMT in reducing postoperative pain and edema as well as improving ROM and functional performance compared with placebo or standard physical therapy in post-arthroplasty patients. METHODS: A systematic search of PubMed, ProQuest, ScienceDirect, and Google Scholar was conducted from inception to May 31, 2025. Only prospective controlled trials assessing PBMT effects on postoperative pain, swelling, ROM, or functional performance following TKA or THA were included. Case reports, uncontrolled studies, and trials focusing on unrelated outcomes were excluded. Article selection involved title, abstract, and full-text screening, with additional studies identified through reference lists. The review is registered in PROSPERO (CRD420251123169). RESULTS: = 133 participants) met the inclusion criteria, three studies focused on TKA, and one study examined THA. PBMT significantly improved postoperative pain and edema reduction in three trials, while two studies demonstrated enhanced ROM and functional outcomes compared with control or placebo interventions. PEDro scores ranged from 8 to 10, indicating moderate-to-high methodological quality. CONCLUSIONS: PBMT shows promising short-term benefits in reducing postoperative pain and swelling and improving functional performance after knee or hip arthroplasty. However, due to heterogeneity in treatment parameters and limited high-quality trials, conclusive evidence remains insufficient. Future large-scale RCTs with standardized PBMT parameters and extended follow-up are warranted to confirm its clinical efficacy.

low-level laser therapytotal knee arthroplastytotal hip arthroplastypostoperative pain
مراجعةوصول مفتوح2026

Comparative Effectiveness of Antihypertensive Agents vs. Control in the Prevention and Management of Preeclampsia: A Network Meta-Analysis

Cureus · مجلد 18 (5) · e109602-e109602

Hypertensive disorders of pregnancy, particularly preeclampsia, are a leading cause of maternal and perinatal morbidity. While antihypertensive therapy is recommended, clinical uncertainty persists regarding the optimal agent to maximize maternal safety while minimizing adverse neonatal outcomes such as neonatal intensive care unit (NICU) admission. This review aimed to evaluate the comparative effectiveness and safety of pharmacological antihypertensive agents versus standard care or placebo in the management of hypertensive disorders of pregnancy through a network meta-analysis (NMA). A systematic review and frequentist random-effects NMA of randomized controlled trials (RCTs) was conducted. Major databases were searched for RCTs comparing antihypertensive agents (labetalol, nifedipine, methyldopa, hydralazine, prazosin) and controls. The primary neonatal outcome evaluated in this network was NICU admission. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework. Twenty-five RCTs were included in the qualitative and quantitative synthesis. The network geometry was anchored by labetalol and nifedipine. In the NMA, no individual antihypertensive agent demonstrated a statistically significant reduction in the risk of NICU admission compared to labetalol. However, probabilistic ranking (P-scores) identified methyldopa (P-score = 0.859) and hydralazine (0.791) as the most favourable interventions for minimizing NICU admissions. Nifedipine showed a slightly elevated, though non-significant, risk profile compared to labetalol (RR 1.09, 95% CI 0.80-1.49). The placebo and standard care ranked lowest. The overall certainty of evidence ranged from moderate to very low due to imprecision and indirectness. Active pharmacological management of hypertension in pregnancy is superior to placebo or standard care. While labetalol and nifedipine remain mainstays for acute blood pressure control, methyldopa and hydralazine probabilistically rank higher for minimizing NICU admissions. These findings support individualized antihypertensive selection based on clinical acuity and maternal-fetal hemodynamics.

preeclampsiahypertensive disorders of pregnancyantihypertensive drugslabetalol
مراجعةمفتوح (مستودع)2026

Network Meta-analysis of Melatonin Receptor Agonists in the Treatment of Primary Sleep Disorders: Efficacy and Safety Profile

Journal of Advanced Trends in Medical Research · مجلد 3 (2) · 65-74

Abstract Background: Melatonin receptor agonists represent an important class of medications for primary sleep disorders, but their comparative efficacy and safety remain incompletely understood. The study was to conduct a comprehensive network meta-analysis (NMA) comparing the efficacy and safety of melatonin receptor agonists for the treatment of primary sleep disorders. Methods: We searched multiple databases from inception to January 2025 for randomised controlled trials (RCTs) evaluating melatonin receptor agonists (ramelteon, tasimelteon, agomelatine and prolonged-release melatonin) in adults with primary sleep disorders. The primary efficacy outcomes were sleep onset latency (SOL), total sleep time (TST) and sleep efficiency. Safety outcomes included adverse events (AEs) and discontinuations. We performed a Bayesian NMA using random-effects models and assessed the certainty of evidence using the CINeMA approach. Results: Fifty-nine RCTs (12,437 participants) were included. All melatonin receptor agonists significantly reduced SOL compared to placebo, with mean differences ranging from −14.8 min (95% credible interval [CRL]: −19.2 to −10.4) for ramelteon to −8.2 min (95% CrI: −13.7 to −2.7) for prolonged-release melatonin. For TST, significant improvements compared to placebo were observed for ramelteon, tasimelteon and agomelatine, but not for prolonged-release melatonin. In head-to-head comparisons, no statistically significant differences were observed among melatonin receptor agonists for most efficacy outcomes. Regarding safety, melatonin receptor agonists demonstrated favorable profiles, with no significant increases in AEs compared to placebo for most agents. Treatment rankings based on surface under the cumulative ranking curve values positioned ramelteon as having the most favorable balance of efficacy and safety among melatonin receptor agonists. Conclusion: Melatonin receptor agonists are effective for improving SOL in primary sleep disorders, with ramelteon showing the most favourable efficacy-safety profile. While their effects are more modest than those of traditional hypnotics, their favourable safety profiles make them valuable options, particularly for vulnerable populations.

melatonin receptor agonistsprimary sleep disordersramelteontasimelteon
مراجعةوصول مفتوح2026

Efficacy and safety of azithromycin in preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis

Frontiers in Pediatrics · مجلد 14 · 1780809-1780809

Introduction Ureaplasma colonization in preterm infants is linked to pulmonary inflammation and bronchopulmonary dysplasia (BPD). Evidence regarding the effectiveness of macrolides, including their prophylactic role in preventing BPD, remains limited. This review aimed to assess whether azithromycin reduces the incidence of BPD or death in preterm infants, with or without Ureaplasma colonization, compared with placebo or no intervention. Methods We followed PRISMA guidelines and searched PubMed, Cochrane Library, Embase, and Google Scholar for randomized controlled trials (RCTs) evaluating azithromycin in preterm infants with unknown or confirmed Ureaplasma infection. Primary outcomes were death and BPD, while secondary outcomes included hospital stay, adverse events, and ventilation or oxygen duration. Studies not focused on preterm infants, lacking Ureaplasma status, or not randomized were excluded. Results A meta-analysis of six randomized controlled trials, including 1,446 preterm infants with unknown or confirmed Ureaplasma status and sample sizes ranging from 80 to 796, compared azithromycin with placebo. No significant reduction was observed in BPD incidence [risk ratio (RR) = 0.92, 95% CI: 0.78–1.09, p = 0.35] or mortality (RR = 0.88, 95% CI: 0.66–1.18, p = 0.39). Heterogeneity was low for mortality ( I 2 = 0%) and moderate for BPD ( I 2 = 61%). Secondary outcomes showed no significant differences in mechanical ventilation days (mean difference=0.07, 95% CI: −0.78 to 0.33, p = 0.58), supplemental oxygen requirement (mean difference=−0.45, 95% CI: −0.98 to 0.07, p = 0.09), or hospitalization duration (mean difference=−0.02, 95% CI: −0.19 to 0.15, p = 0.85). Heterogeneity ( I 2 ) was 94% for supplemental oxygen, 71% for mechanical ventilation, and 0% for hospitalization duration. Risk-of-bias assessment identified two studies with low risk and four with unclear risk, indicating acceptable methodological quality. Conclusion This systematic review and meta-analysis evaluated azithromycin efficacy and safety in preventing BPD and reducing mortality in preterm infants. No significant reduction in BPD or mortality was observed with azithromycin compared with placebo. Secondary outcomes, including ventilation duration, supplemental oxygen use, and hospitalization length, showed no improvement. However, heterogeneity among secondary outcomes was moderate to high, and included studies were limited. Systematic Review Registration PROSPERO CRD42024572847.

azithromycinbronchopulmonary dysplasiapreterm infantsneonatal mortality